Skip to main content

Table 3 Pooled relative risks of all-cause mortality for categorical and continuous analyses in subgroups

From: Effects of blood triglycerides on cardiovascular and all-cause mortality: a systematic review and meta-analysis of 61 prospective studies

Sub-groups

Triglyceride group (mg/dl)

Per 1 mmol/L TG

<90

90-146

150-199

≥200

 

N*

RR (95% CI)

N*

RR†

N*

RR (95% CI)

N*

RR (95% CI)

N*

RR (95% CI)

Age (year)

  <50

3

0.88 (0.78, 1.00)

5

1.00

5

1.14 (1.05, 1.24)

5

1.20 (0.99, 1.46)

8

1.13 (1.05, 1.21)

  ≥50

9

0.97 (0.85, 1.11)

9

1.00

9

1.07 (0.97, 1.18)

3

1.20 (0.97, 1.48)

14

1.12 (1.07, 1.17)

  P value

 

0.311

   

0.329

 

0.982

 

0.845

Gender

  Male

8

0.95 (0.84, 1.09)

9

1

9

1.12 (1.02, 1.22)

5

1.23 (1.09, 1.38)

14

1.09 (1.04, 1.13)

  Female

6

0.91 (0.84, 0.99)

6

1

6

1.17 (0.99, 1.39)

2

1.01 (0.59, 1.74)

10

1.24 (1.15, 1.32)

  Mixed

3

1.00 (0.85, 1.17)

4

1

4

1.11 (1.01, 1.21)

3

1.17 (1.01, 1.35)

6

1.08 (1.03, 1.13)

  P value

 

0.577

   

0.621

 

0.491

 

0.001

Follow-up (year)

  <15

6

0.89 (0.84, 0.94)

7

1.00

7

1.11 (0.97, 1.26)

4

1.26 (1.06, 1.51)

14

1.05 (1.02, 1.07)

  ≥15

6

0.94 (0.79, 1.11)

7

1.00

7

1.09 (1.02, 1.16)

4

1.15 (0.93, 1.41)

8

1.22 (1.16, 1.29)

  P value

 

0.569

   

0.773

 

0.490

 

0.000

Fast status

  Fast

8

1.01 (0.86, 1.20)

11

1.00

11

1.08 (0.98, 1.18)

5

1.27 (1.09, 1.48)

15

1.12 (1.06, 1.19)

  Nonfast

2

0.91 (0.86, 0.98)

3

1.00

3

1.14 (1.04, 1.24)

3

1.11 (0.88, 1.40)

6

1.11 (1.03, 1.19)

  Others§

2

0.79 (0.63, 0.99)

2

1.00

2

1.11 (0.89, 1.38)

0

-

1

1.19 (1.09, 1.30)

  P value

 

0.258

   

0.381

 

0.335

 

0.740

Geographic location

  Europe/America

10

0.96 (0.87, 1.06)

11

1.00

11

1.09 (1.00,1.19)

6

1.19 (0.98, 1.45)

16

1.12 (1.06, 1.17)

  Asia-Pacific

2

0.81 (0.59, 1.11)

3

1.00

3

1.12 (1.02, 1.23)

2

1.22 (1.08, 1.39)

6

1.13 (1.08, 1.20)

  P value

 

0.302

   

0.633

 

0.813

 

0.640

Quality score

  <7

5

0.90 (0.86, 0.94)

7

1.00

7

1.15 (1.08, 1.24)

4

1.22 (1.07, 1.40)

10

1.13 (1.08, 1.18)

  7-9

7

0.95 (0.77, 1.17)

7

1.00

7

1.03 (0.91, 1.17)

4

1.19 (0.91, 1.57)

12

1.11 (1.05, 1.18)

  P value

 

0.594

   

0.116

 

0.869

 

0.707

Sample size

  <4000

7

0.97 (0.75, 1.25)

7

1.00

7

1.03 (0.92, 1.15)

4

1.22 (1.03, 1.45)

13

1.14 (1.07, 1.22)

  ≥4000

5

0.92 (0.86, 0.96)

7

1.00

7

1.14 (1.04, 1.24)

4

1.18 (0.95, 1.45)

9

1.09 (1.04, 1.14)

  P value

 

0.729

   

0.155

 

0.778

 

0.190

Free of CVDs at baseline

  Yes

5

0.94 (0.85, 1.03)

6

1.00

6

1.07 (0.99, 1.16)

5

1.24 (0.99, 1.56)

13

1.10 (1.04, 1.16)

  No

7

0.97 (0.80, 1.16)

8

1.00

8

1.10 (0.99, 1.23)

3

1.14 (1.00, 1.30)

9

1.13 (1.07, 1.20)

  P value

 

0.711

   

0.663

 

0.519

 

0.480

Adjustment

  Minimally

9

0.86 (0.72, 1.03)

10

1.00

10

1.14 (0.99, 1.30)

7

1.38 (1.13, 1.67)

8

1.12 (1.01, 1.24)

  Maximally

9

0.94 (0.80, 1.11)

10

1.00

10

1.07 (0.99, 1.17)

7

1.18 (1.01, 1.38)

8

1.07 (1.01, 1.13)

  P value

 

0.466

   

0.487

 

0.222

 

0.432

Adjustment for TC

  Yes

5

0.84 (0.7, 0.99)

5

1.00

5

1.03 (0.93, 1.14)

2

1.10 (0.88, 1.38)

11

1.10 (1.05, 1.15)

  No

7

1.00 (0.89, 1.12)

9

1.00

9

1.12 (1.02, 1.24)

8

1.27 (1.16, 1.40)

11

1.14 (1.07, 1.21)

  P value

 

0.103

   

0.225

 

0.239

 

0.382

Adjustment for HDL

  Yes

2

1.03 (0.93, 1.14)

2

1.00

2

1.02 (0.89, 1.17)

1

1.35 (1.09, 1.66)

4

1.07 (1.04, 1.11)

  No

10

0.92 (0.82, 1.02)

12

1.00

12

1.11 (1.03, 1.20)

8

1.14 (0.93, 1.39)

18

1.12 (1.07, 1.17)

  P value

 

0.115

   

0.296

 

0.250

 

0.132

  1. *The number of cohorts.
  2. †Reference group.
  3. §Others included mixed and unknown ones.
  4. RR, relative risk; CI, confidence interval; CVDs: cardiovascular diseases; HDL: high-density lipoprotein.
  5. TG: triglycerides; TC: total cholesterol.